Fact-Checkers Find Few Flaws in Clinton's Healthcare Claims

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: The Hill, Sam Baker (9/6/12)

"Self-proclaimed fact-checkers have drawn plenty of criticism from both parties, as well as neutral observers, and many individual assessments of 'fact' are highly debatable. In the aggregate, though, the fact-checkers haven't found much to complain about in Clinton's healthcare comments."

The Hill, Sam Baker

Bill Clinton's long, detailed arguments on healthcare are mostly holding up under scrutiny from the cottage industry of political fact-checkers.

Healthcare was a big part of Clinton's policy-laden speech Wednesday night at the Democratic convention in Charlotte, N.C. He defended President Obama's healthcare law, including its controversial Medicare savings, and took a hard swipe at Republicans' proposals for Medicaid.

Self-proclaimed fact-checkers have drawn plenty of criticism from both parties, as well as neutral observers, and many individual assessments of "fact" are highly debatable. In the aggregate, though, the fact-checkers haven't found much to complain about in Clinton's healthcare comments.

The biggest criticism centers around Clinton's claim that healthcare costs aren't rising as quickly as they did in the past. . .View Full Article

US$12 Billion RNA Deal Triggers Sector Shakeup
Source: Streetwise Reports (11/14/2025)

Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.

Lead Drug Faces Uncertain FDA Path After Phase 3 Miss
Source: Streetwise Reports (11/13/2025)

aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward.

Preclinical Compounds Perform Better Than Existing Drugs
Source: Dr. Douglas Loe (11/13/2025)

Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report.

Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials
Source: Streetwise Reports (11/12/2025)

Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management.

Biotech to Fast Track Phase 3 Depression Trial
Source: Dr. Myles Minter (10/30/2025)

Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report.